Αναζήτηση

σε πρόσθεσε στο Health

2026-04-08 09:59:52 -

Atopic Dermatitis Market: How Are New Biologic Mechanisms Expanding AD Treatment Options?

Novel biologic mechanisms for atopic dermatitis — tralokinumab (Adbry), lebrikizumab (Ebglyss), nemolizumab, and pipeline biologics targeting IL-13 specifically, IL-31 itch signaling, TSLP, and OX40L — represent the diversification of AD biologic mechanisms beyond the established IL-4/IL-13 dual blockade of dupilumab, with the Atopic Dermatitis Market reflecting biologic diversity...

0 Σχόλια 0 Μοιράστηκε 9 Views 0 Προεπισκόπηση